… This study was a multicenter, open-label, phase-II clinical trial evaluating the safety and …
with EGFR-sensitive mutations after failure of EGFR-TKI therapy (NCT03513666). The study was …

… Background: EGFR mutant NSCLC is exquisitely sensitive to EGFR tyrosine kinase inhibitors
(… This trial is the first to prospectively test the efficacy of adjuvant erlotinib in EGFR-mutant …

… ) in patients with prior systemic treatment for EGFR mutation–positive NSCLC. Based on the
… EGFR mutation–positive NSCLC. We thus conducted this multicenter phase 2 clinical trial to …

… of large-scale screening for EGFR mutations and efficacy of erlotinib in … mutations in this
study was similar to those typically reported with first-line cytotoxic chemotherapy in this setting [2…

… Background: Cancers with activating EGFR mutations are exquisitely sensitive to EGFR …
EGFR mutants. This prospective trial investigates the safety and efficacy of adjuvant erlotinib in …

… active against most uncommon EGFR mutations, apart from exon … osimertinib for NSCLC
with uncommon EGFR mutations. Here, we … EGFR mutations from a multicenter phase II study. …

… factor in this trial. Because of this limitation, we undertook this phase 2 trial to examine the
combination of erlotinib and bevacizumab in patients with EGFR mutation-positive NSCLC. …

… We performed a multicentre phase II study examining the use of gefitinib for advanced
NSCLC in patients with EGFR mutations, prospectively recruiting patients at the time of genetic …

… In this study, we report a phase I/II study result to determine the recommended phase II dose
(… Other key inclusion criteria for phase II included an EGFR T790M mutation-positive patient …

… antibody to EGFR, in … of EGFR through use of a monoclonal antibody is safe and effective
in patients with esophagogastric cancer, we initiated a multi-institutional phase II study of …